Clinical trials: Phase I
Type 2 Diabetes Mellitus
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
The purpose of this study is to evaluate the effect of steady-state ranolazine 500 mg bid on the steady state pharmacokinetics (PK) of metformin in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01546558
- Testing
- Metformin, Ranolazine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Healthy
Clinical Efficacy of Single-Use of Peroxyl Mouthwash for Reducing Bacteria in Saliva and Bioaerosol Contamination
To evaluate the anti-bacterial, pre-procedural, clinical efficacy of Peroxyl mouthwash (1.5% hydrogen peroxide) in saliva and the reduction of bioaerosol contamination as compared to a matching placebo mouthwash (0.0% hydrogen…
- Trial name
- NCT04626778
- Testing
- Peroxyl Mouthwash
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Healthy
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
- Trial name
- NCT02657408
- Testing
- BI 1026706
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers
This is a open label, single center, single oral dose, study of PRT054021, in healthy subjects.
- Trial name
- NCT01765868
- Testing
- Betrixaban
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Recurrent Glioblastoma IDH Wildtype
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
This is an open-label, single-arm, dose-escalation and expansion Phase 1/2 clinical trial designed to evaluate the safety, tolerability and efficacy of P134 cells in patients with recurrent glioblastoma, to explore the maximum…
- Trial name
- NCT07318818
- Testing
- P134 cell injection
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Prostatic Neoplasms
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
- Trial name
- NCT02616185
- Testing
- PF-06755992, PF-06755990, TDS-IM Electroporation Device
- Where
- 19 sites in United States
- Volunteers
- 91 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. TBI 302 is being developed for the treatment of inoperable HCC by intravenous infusion.
- Trial name
- NCT03908840
- Testing
- TBI 302
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Evolve Biologics
Gout, Hyperuricemia
Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults
This is an open-label, randomized, crossover, single dose study. Two single doses of LC350189(tablet or capsule formulations) will be administered with a washout period of at least 4-day between the doses to investigate the…
- Trial name
- NCT04886050
- Testing
- LC350189 Tablet, LC350189 Capsule
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- LG Chem
Relapsed or Refractory Multiple Myeloma
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
- Trial name
- NCT05918250
- Testing
- mRNA-2736
- Where
- 13 sites in United States, Canada
- Sponsor
- ModernaTX, Inc.
Healthy
A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
This is an open-label, 2-cohort study to evaluate the mutual DDI potential between denifanstat and resmetirom in healthy adult participants.
- Trial name
- NCT07216313
- Testing
- Denifanstat, Resmetirom
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sagimet Biosciences Inc.
Cancer, Tumors
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.
- Conditions
- Cancer, Tumors, Neoplasm, Malignancy
- Trial name
- NCT03251924
- Testing
- BMS-986226, Nivolumab, Ipilimumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Health Subjects
a Phase I PK Study in Healthy Male Subjects. 2 Groups of Healthy Male Subjects
Tolvaptan oral administraction phase I PK clinical trial. Two groups of healthy male subjects. One group receives single dose of Tolvaptan. The other group receives multi dose of Tolvaptan.
- Trial name
- NCT07166796
- Testing
- singe dose 15mg, single dose 30mg, single dose 60mg
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Otsuka Beijing Research Institute
Dry Eye Disease
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
The objective of this study is to assess safety and efficacy of DE-089 ophthalmic solution in patients with dry eye disease in Taiwan.
- Trial name
- NCT03216096
- Where
- 2 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Healthy
Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects
The purpose of this study is to determine how well tolerated and safe AZD5069 is at different dose levels in healthy male and/or females.
- Trial name
- NCT00953888
- Testing
- AZD5069
- Where
- United Kingdom
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A First-time-in-human Study of BGB149
This clinical trial is a Phase I, first-in-human. The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of BGB149 after single IV doses in healthy male and…
- Trial name
- NCT03795142
- Testing
- BGB149
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
mCRPC or Advanced/Metastatic Solid Tumors
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
- Trial name
- NCT07533708
- Testing
- HLX3902
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Henlius Biotech
Upper Limb Spasticity Post-Stroke
Phase 1 Trial of JTM201 in Subjects With Post-stroke Upper Limb Spasticity
Phase 1 trial to evaluate the safety and efficacy of JTM201 compared with 'Botox® Inj.' in subjects with post-stroke upper limb spasticity
- Trial name
- NCT07292025
- Testing
- JTM201 in normal saline, BOTOX 100U in normal saline
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Jetema Co., Ltd.
Tennis Elbow
Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow
This study is testing a drug called TenoMiR that is being developed for the treatment of tennis elbow (lateral epicondylitis). The study drug is a new compound that works by improving the quality of the collagen which helps…
- Trial name
- NCT04670289
- Testing
- TenoMiR (Low Dose), TenoMiR (Medium Dose), TenoMiR (High Dose)
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Causeway Therapeutics
Diabetes Mellitus, Type 1
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
Phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid insulin aspart (AT247), NovoLog® and Fiasp® in participants…
- Trial name
- NCT05184868
- Testing
- AT247, NovoLog, Fiasp
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arecor Limited
Health Adults, Asthma
Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma
This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study evaluating HXN-1013 in healthy participants and participants with mild-to-moderate asthma.
- Trial name
- NCT07900568
- Testing
- HXN-1013
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.